3 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 3 Not applicable, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Hyperlipoproteinemia Type III: new trials by email Literature Review of Hyperlipoproteinemia Type III trials Research Report on Hyperlipoproteinemia Type III
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis Whole Genome Sequencing - Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Recessive | Not applicable | Recruiting | Abu Dhabi Health Services Company | 40 | 2024-07-29 | 2025-03-25 |
| Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia Research-based genetic test for Familial Hypercholesterolemia - Familial Hypercholesterolemia, Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B | Not applicable | Completed | University of British Columbia | 140 | 2022-01-01 | 2026-05-01 |
| Genetic Testing and Motivational Counseling for FH Genetic Testing, Motivational Counseling, Lipid analysis - Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1 | Not applicable | Active not recruiting | National Medical Research Center for Therapy and Preventive Medicine | 180 | 2020-06-15 | 2024-12-17 |
| Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia Evolocumab Auto-Injector [Repatha], Placebos - Familial Dysbetalipoproteinemia, Hyperlipoproteinemia Type III | Phase 4 | Unknown | UMC Utrecht | 30 | 2019-08-01 | 2019-01-22 |
| HoFH, the International Clinical Collaborators Registry Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence. - Homozygous Familial Hypercholesterolemia | Recruiting | University of Pennsylvania | 1000 | 2017-01-24 | 2025-12-18 | |
| DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk" Dysbetalipoproteinemia | Unknown | Hospices Civils de Lyon | 50 | 2013-01-01 | 2013-01-28 | |
| Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder. torcetrapib/atorvastatin, atorvastatin, fenofibrate - Hyperlipoproteinemia Type III | Phase 3 | Terminated | Pfizer | 41 | 2005-03-01 | 2012-02-17 |
| Type III Dysbetalipoproteinemia Rosuvastatin, rosuvastatin, pravastatin - Hyperlipoproteinemia Type III | Phase 3 | Completed | AstraZeneca | 30 | 2005-02-01 | 2010-11-19 |
| Evaluation of Lipoproteins Balanced diet - Evaluation of Plasma Lipoproteins | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1017 | 1979-01-01 | 2026-08-18 | |
| Compassionate Use of Evinacumab Evinacumab - Pediatric Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (HTG) | Approved for marketing | Regeneron Pharmaceuticals | 2025-10-28 |
Hypercholesterolemia (3) · Hyperlipoproteinemia Type II (3) · Acute Coronary Syndrome (1) · Homozygous Familial Hypercholesterolemia (1) · Hypercholesterolemia, Autosomal Dominant, 3 (1) · Hypertriglyceridemia (1) · Medication Adherence (1) · Multiple Pterygium Syndrome, Autosomal Dominant (1) · Myocardial Infarction (1) · Non-ST Elevated Myocardial Infarction (1) · Patient Compliance (1) · ST Elevation Myocardial Infarction (1) · Treatment Adherence and Compliance (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Dyslipidemias (10) · Genetic Diseases, Inborn (10) · Hyperlipidemias (10) · Hyperlipoproteinemias (10) · Lipid Metabolism Disorders (10) · Lipid Metabolism, Inborn Errors (10) · Metabolic Diseases (10) · Metabolism, Inborn Errors (10) · Nutritional and Metabolic Diseases (10) · Behavior (1) · Cardiovascular Diseases (1) · Health Behavior (1) · Heart Diseases (1) · Hyperlipoproteinemia Type II (1)
Atorvastatin (1) · Demography (1) · Diet (1) · Fenofibrate (1) · Genetic Testing (1) · Genotype (1) · Motivational Interviewing (1) · Pravastatin (1) · Referral and Consultation (1) · Rosuvastatin Calcium (1) · Whole Genome Sequencing (1) · evinacumab (1) · evolocumab (1) · torcetrapib (1)
Abu Dhabi Health Services Company (1) · AstraZeneca (1) · Hospices Civils de Lyon (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Medical Research Center for Therapy and Preventive Medicine (1) · Pfizer (1) · Regeneron Pharmaceuticals (1) · UMC Utrecht (1) · University of British Columbia (1) · University of Pennsylvania (1)
United States (3) · Canada (2) · South Africa (2) · France (1) · Netherlands (1) · Norway (1) · Russia (1) · United Arab Emirates (1)
Abdulmajeed BS Alzubaidi, MD (1) · Alexandra Ershova, MD, PhD (1) · Alexey Meshkov, MD, PhD (1) · Erik J Koornneef, PHD (1) · Frank LJ Visseren, prof (1) · Liam Brunham, MD PhD (1) · Marina Cuchel, MD, PhD (1) · Mhy-Lanie Adduru, MD (1) · Robert D Shamburek, M.D. (1) · Salah Eldin HM Hu, MD (1)